Literature DB >> 15746501

Defining and measuring clinical effectiveness in the treatment of schizophrenia.

Henry A Nasrallah1, Steven D Targum, Rajiv Tandon, Jeffrey S McCombs, Ruth Ross.   

Abstract

OBJECTIVES: Expectations in treating schizophrenia are expanding beyond just controlling psychotic symptoms to include functional recovery. This report describes an approach to define and measure the clinical effectiveness of treatment in achieving these objectives.
METHODS: A comprehensive literature review established that there is limited information about the meaning of the term "clinical effectiveness." To address this gap a consensus conference of schizophrenia researchers was held to consider the components of clinical effectiveness in real-world community practice and how these components can best be measured.
RESULTS: The consensus of the researchers was that effective clinical treatment is characterized by four outcome domains: symptoms of disease, treatment burden, disease burden, and health and wellness. A clinical instrument to measure these four domains was constructed: Global Outcome Assessment of Life in Schizophrenia (GOALS). In using GOALS, clinicians rate each of the four domains on a scale of 1, very much improved, to 7, very much worse. Field-testing of this instrument is planned.
CONCLUSIONS: Effective treatment interventions that combine optimal pharmacotherapy and targeted psychosocial treatments are raising expectations about the prospects of functional recovery among patients with schizophrenia. GOALS is proposed as one tool that can provide busy clinicians with a simple, objective measure of the effectiveness and outcomes of the clinical treatment they provide to patients with schizophrenia.

Entities:  

Mesh:

Year:  2005        PMID: 15746501     DOI: 10.1176/appi.ps.56.3.273

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  30 in total

1.  [PSP Scale: German version of the Personal and Social Performance Scale: valid instrument for the assessment of psychosocial functioning in the treatment of schizophrenia].

Authors:  D Schaub; G Juckel
Journal:  Nervenarzt       Date:  2011-09       Impact factor: 1.214

Review 2.  Progress in defining optimal treatment outcome in schizophrenia.

Authors:  Gary Remington; George Foussias; Ofer Agid
Journal:  CNS Drugs       Date:  2010-01       Impact factor: 5.749

3.  Effects of haloperidol on cognition in schizophrenia patients depend on baseline performance: a saccadic eye movement study.

Authors:  Shelly L Babin; Ashley J Hood; Adel A Wassef; Nina G Williams; Saumil S Patel; Anne B Sereno
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-06-13       Impact factor: 5.067

4.  Recovery as a Process in Severe Mental Illnesses.

Authors:  Mustafa Yildiz
Journal:  Noro Psikiyatr Ars       Date:  2015-03-01       Impact factor: 1.339

5.  Remission and recovery during the first outpatient year of the early course of schizophrenia.

Authors:  Joseph Ventura; Kenneth L Subotnik; Lisa H Guzik; Gerhard S Hellemann; Michael J Gitlin; Rachel C Wood; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2011-07-18       Impact factor: 4.939

6.  [Guideline compliance in the treatment of schizophrenic patients. Introduction of a computer-assisted treatment pathway].

Authors:  F Godemann; K Blittersdorf; M Poschenrieder; H Klimitz; I Hauth; H Gutzmann
Journal:  Nervenarzt       Date:  2010-05       Impact factor: 1.214

7.  The illness and everyday living: close interplay of psychopathological syndromes and psychosocial functioning in chronic schizophrenia.

Authors:  Daniela Schaub; Martin Brüne; Elisabeth Jaspen; Frank-Gerald Pajonk; Hans-Werner Bierhoff; Georg Juckel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-07-22       Impact factor: 5.270

8.  Recovery From Schizophrenia: The Case of Mexican-Origin Consumers and Family Caregivers.

Authors:  Maria M Santos; Alex Kopelowicz; Steven R López
Journal:  J Nerv Ment Dis       Date:  2018-06       Impact factor: 2.254

9.  A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting.

Authors:  Ming-Hong Hsieh; Wei-Wen Lin; Shao-Tsu Chen; Kao-Ching Chen; Kuang-Peng Chen; Nan-Ying Chiu; Chao Huang; Ching-Jui Chang; Cheng-Hsiu Lin; Te-Jen Lai
Journal:  Ann Gen Psychiatry       Date:  2010-09-17       Impact factor: 3.455

10.  The abilities of improved schizophrenia patients to work and live independently in the community: a 10-year long-term outcome study from Mumbai, India.

Authors:  Amresh Kumar Srivastava; Larry Stitt; Meghana Thakar; Nilesh Shah; Gurusamy Chinnasamy
Journal:  Ann Gen Psychiatry       Date:  2009-10-13       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.